The Raleigh biotech priced its Nasdaq debut at $13 a share to fund mizagliflozin, an oral drug aimed at the dangerous blood-sugar crashes some patients face after bariatric surgery.
Kobe University researchers mass-produced iPSC-derived γδ T cells that cut tumor weight by up to 88% in mice — a step toward cheaper, ready-made cell therapy.
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.
Gladstone scientists engineered human interneurons from stem cells and used them to repair the nerve pathways that control breathing after spinal cord injury.
Columbia engineers linked lab-grown human bone and lung tissue on a chip and watched circulating breast-cancer cells choose their targets — and soften them up in advance.
Scientists found lymph-node-like structures in skull bone marrow that spring into action against brain tumors — and a scalp gel that revs them up improved survival in mice.
Stanford and UCSF researchers showed the Alzheimer’s protein tau invades mitochondria and forces electrons to flow backward, and an experimental drug blocked the damage.
The European Commission approved teclistamab plus daratumumab for relapsed multiple myeloma after a trial cut the risk of progression or death by more than 80%.
Revolution Medicines’ Rasonque (daraxonrasib) is the first targeted therapy to hit RAS — the mutation driving over 90% of pancreatic cancers — extending median survival to 13.2 months versus 6.7 on chemo.
In mice with glioblastoma, engineered nanoparticles lit up tumor clusters as small as a hair’s width during surgery, then destroyed microscopic leftover cells — and every treated animal survived.
While the industry chases GLP-1 agonists for weight loss, Amylyx went the other way — and its GLP-1 antagonist cut severe hypoglycemic events by 55% in a late-stage trial.
PIKTOR, an oral combination that hits the PI3K/AKT/mTOR pathway, won fast-track status alongside chemotherapy for endometrial cancer that has progressed despite prior treatment.